Publication | Closed Access

Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial

ThrombosisHemodialysisSignificant Extravascular HaemolysisMedicineHematologyHemostasisCoagulopathyBleeding DisorderChronic Kidney DiseaseAnticoagulantNephrologyParoxysmal Nocturnal HaemoglobinuriaAnesthesiology